NOV 14, 2020 7:15 AM PST

New intravenous anti-cancer therapy crosses blood-brain barrier

New research from the University of Michigan reports for the first time a new synthetic protein nanoparticle that is able to deliver anti-cancer drugs directly to brain tumors. This drug is the first intravenous medication capable of crossing the blood-brain barrier.

The study was conducted in mice models to assess the effects of the drug on glioblastoma, which is the most common and aggressive form of brain cancer in adults. The research team found that seven out of eight mice administered the intravenous therapy experienced long-term survival. Furthermore, when those seven mice experienced a recurrence of glioblastoma, the research showed that their immune responses were successfully activated.

"It's still a bit of a miracle to us," said co-author Joerg Lahann, the Wolfgang Pauli Collegiate Professor of Chemical Engineering. "Where we would expect to see some levels of tumor growth, they just didn't form when we rechallenged the mice. I've worked in this field for more than 10 years and have not seen anything like this."

As Lahann implies, these findings have huge implications. The median survival for patients with glioblastoma is around 18 months and the average 5-year survival rate is below 5%. This intravenous nanoparticle delivery therapy could potentially lead to improved treatments for the deadly cancer.

"This is a huge step toward clinical implementation," said co-senior author of the study, Maria Castro, the R.C. Schneider Collegiate Professor of Neurosurgery. "This is the first study to demonstrate the ability to deliver therapeutic drugs systemically, or intravenously, that can also cross the blood-brain barrier to reach tumors."

Photo: Pexels

The nanoparticle therapy uses the building blocks of a protein present in the blood known as human serum albumin, which is one of the rare molecules capable of crossing the blood-brain barrier. According to the team, their technique could be eventually be adapted to deliver other small-molecule drugs and therapies to solid-based tumors.

Sources: Nature, Science Daily

About the Author
  • Kathryn is a curious world-traveller interested in the intersection between nature, culture, history, and people. She has worked for environmental education non-profits and is a Spanish/English interpreter.
You May Also Like
SEP 14, 2020
Genetics & Genomics
Why Defects in One Gene Can Lead to Cancer in Kids
SEP 14, 2020
Why Defects in One Gene Can Lead to Cancer in Kids
While they may occur in adults, a rare, aggressive type of brain cancer called atypical teratoid rhabdoid tumors tend to ...
SEP 18, 2020
Cancer
Itraconazole: the key is in the dosage
SEP 18, 2020
Itraconazole: the key is in the dosage
Precision medicine specific to a patient’s genetics or immune system is spearheading new paths of cancer treatment ...
OCT 18, 2020
Microbiology
Mouth Microbes Play a Role in Oral Cancer Development
OCT 18, 2020
Mouth Microbes Play a Role in Oral Cancer Development
Oral hygiene is not only important for keeping teeth and gums healthy; it can also affect a person's health in general.
NOV 07, 2020
Cancer
Newly identified biomarker sheds light on antiangiogenic drug responses
NOV 07, 2020
Newly identified biomarker sheds light on antiangiogenic drug responses
A study published last week in the journal EMBO Molecular Medicine provides insight into the molecular mechanisms t ...
NOV 12, 2020
Immunology
Anti-bodies against a sugar present in meat and dairy products can increase the risk of Colorectal Cancer
NOV 12, 2020
Anti-bodies against a sugar present in meat and dairy products can increase the risk of Colorectal Cancer
Nutrition is essential to health; what we eat in our daily diet affects our overall health condition and what diseases w ...
NOV 23, 2020
Cancer
Platelets May Protect Cancer Against PD-1 Therapies
NOV 23, 2020
Platelets May Protect Cancer Against PD-1 Therapies
One of cancer’s greatest tools is its ability to manipulate the immune system. Many cancer therapies have arisen t ...
Loading Comments...